Similarly, CTLA-4 blockade in MBP-reactive T cells from MS patients and healthy controls during stimulation resulted in a proliferative and enhanced cytokine response, whereas this effect was much lower in MS patients, inferring that CTLA-4's regulatory function in MS patients might be compromised [152]. Here, CTLA4 is linked to myeloid sarcoma.